United States of America, ex rel v. Fife Dermatology PC

District Court, D. Nevada·Decided December 22, 2021·No. 2:17-cv-02191·Unknown

Opinion

* * *

UNITED STATES OF AMERICA and THE Case No. 2:17-CV-2191 JCM (DJA) STATE OF NEVADA ex rel. THOMAS MOONEY, and THOMAS MOONEY, ORDER INDIVIDUALLY, Plaintiff(s),

v.

FIFE DERMATOLOGY, PC, d/b/a SURGICAL DERMATOLOGY & LASER CENTER, et al,,

Defendant(s).

Presently before the court is defendant Vivida Dermatology’s1 (“Vivida”) motion to dismiss plaintiff Thomas Mooney’s (“Mooney”) complaint (ECF No. 1). (ECF No. 37). Mooney filed a response (ECF No. 44), to which Vivida replied (ECF No. 45). Before responding, Mooney filed his first amended complaint (ECF No. 41). Vivida did not respond, instead arguing that its motion to dismiss also applies to the first amended complaint. Also before the court is Mooney’s motion for leave to amend his first amended complaint. (ECF No. 53). Vivida filed a response (ECF No. 54), to which Mooney replied (ECF No. 59). I. Background On April 1, 2017, Mooney began employment as Vivida’s chief operating officer. (ECF No. 41 at 1–2). Soon after, Mooney developed a belief that providers and staff at Vivida—with at least the knowledge of Vivida’s co-owners and co-defendants in this matter, Douglas Fife 1 Vivida Dermatology f/k/a Fife Dermatology, PC d/b/a Surgical Dermatology & Laser Center. (“Douglas”) and Heather Fife (“Heather”)—were committing fraud upon the United States and the State of Nevada by improperly billing Medicare and Nevada Medicaid. (Id. at 3). Mooney frequently discussed his concerns with Douglas. While Douglas allegedly said he would “look into” Mooney’s concerns, those concerns remained unaddressed when Vivida discharged Mooney on June 21, 2017. (Id. at 4–5). On August 15, 2017, Mooney—along with the United States of America and the State of Nevada, ex rel.—filed a complaint under seal alleging several qui tam claims under the False Claims Act and the Nevada False Claims Act. (ECF No. 1). Mooney also asserted claims against Vivida, Douglas, and Heather for retaliation under 31 U.S.C. § 3730(h) and wrongful discharge under Nevada state law. (Id. at 24–25). On June 4, 2020, Mooney voluntarily dismissed all claims against Vivida except for his retaliation and wrongful discharge claims. (ECF No. 21). The United States of America and the State of Nevada consented to dismissal, concluding that the evidence of fraud was insufficient to justify further government investigation. (ECF No. 22 at 3). The court then unsealed Mooney’s complaint on August 19, 2020. (ECF No. 24). On April 16, 2021, Vivida filed the instant motion to dismiss Mooney’s remaining claims against Vivida. (ECF No. 37). In response, Mooney filed his first amended complaint, alleging just two claims—retaliation under § 3730(h) and a new state law claim for breach of contract. (ECF No. 41). Mooney now moves for leave to amend his first amended complaint (ECF No. 53) with three new state law claims—violation of NRS § 613.010, breach of the implied covenant of good faith and fair dealing, and negligent misrepresentation. (ECF No. 53-2). II. Legal Standard The court may dismiss a complaint for “failure to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). For a plaintiff to prevail against a Rule 12(b)(6) motion, every pleading must contain a “short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P(8). Although Rule 8 does not require detailed factual allegations, it does require more than “labels and conclusions” or a “formulaic recitation of the elements of a cause of action.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). In other words, a pleading must have plausible factual allegations that cover “all the material elements necessary to sustain recovery under some viable legal theory.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 562 (2007) (citation omitted) (emphasis in original); see also Mendiondo v. Centinela Hosp. Med. Ctr., 521 F.3d 1097, 1104 (9th Cir. 2008). If the court grants a Rule 12(b)(6) motion to dismiss, it should grant leave to amend unless the deficiencies cannot be cured by amendment. DeSoto v. Yellow Freight Sys., Inc., 957 F.2d 655, 658 (9th Cir. 1992). That is, the court need not give leave to amend when it determines that the pleading is futile or “could not possibly be cured by the allegation of other facts.” Lopez v. Smith, 203 F.3d 1122, 1127–28 (9th Cir. 2000) (quoting Doe v. United States, 58 F.3d 494, 497 (9th Cir. 1995)). “Rule 15(c) states that ‘[a]n amendment to a pleading relates back to the date of the original pleading when . . . the amendment asserts a claim . . . that arose out of the conduct, transaction, or occurrence set out—or attempted to be set out—in the original pleading. . . .’” Bank of New York Mellon as Tr. for Certificateholders of CWALT, Inc. v. SFR Invs. Pool 1,

Free access — add to your briefcase to read the full text and ask questions with AI

United States of America, ex rel v. Fife Dermatology PC, (D. Nev. 2021).

United States of America, ex rel v. Fife Dermatology PC (United States of America, ex rel v. Fife Dermatology PC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Mendiondo v. Centinela Hospital Medical Center
521 F.3d 1097 (Ninth Circuit, 2008)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)
ASARCO, LLC v. Union Pacific Railroad
765 F.3d 999 (Ninth Circuit, 2014)